Siegfried Expects A Stronger Second-Half For 2020
Company Reported First-Half Production Interruptions Due To COVID-19
Executive Summary
Siegfried reported a stable first half on the back of 7% growth in sale of drug products despite COVID-19 impacts. It expects growth in sales and EBITDA margin to increase for the second half of 2020.
You may also be interested in...
Siegfried Achieves Desired Scale After Completing Novartis Plant Deal
Siegfried has completed the acquisition of two Spanish manufacturing facilities from Novartis, in a move that will significantly enhance the Swiss CDMO’s capacity.
Generics Industry Counts Cost Of Stormy Second Quarter
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.